Brexafemme®

Drugs - Brexafemme® (ibrexafungerp) [Scynexis, Inc.]

April 2022

Therapeutic area - Antifungals, Oral

Initial approval criteria

• Patient must have a diagnosis of vulvovaginal candidiasis AND
• Patient is not pregnant AND
• Patient is at least 18 years of age or patient is less than 18 years of age and post menarche AND
• Patient has tried and failed a trial of oral fluconazole, unless contraindicated for the current episode

Quantity limits

• 4 tablets per day per treatment

Questions?

MHCP Provider Resource Center 651-431-2700 or 800-366-5411